Cargando…

CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies

In the past decade, the emergence of chimeric antigen receptor (CAR) T-cell therapy has led to a cellular immunotherapy revolution against various cancers. Although CAR-T cell therapies have demonstrated remarkable efficacy for patients with certain B cell driven hematological malignancies, further...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jiawen, Huang, Xiaobing, Huang, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557333/
https://www.ncbi.nlm.nih.gov/pubmed/36248810
http://dx.doi.org/10.3389/fimmu.2022.1019115
_version_ 1784807281911660544
author Huang, Jiawen
Huang, Xiaobing
Huang, Juan
author_facet Huang, Jiawen
Huang, Xiaobing
Huang, Juan
author_sort Huang, Jiawen
collection PubMed
description In the past decade, the emergence of chimeric antigen receptor (CAR) T-cell therapy has led to a cellular immunotherapy revolution against various cancers. Although CAR-T cell therapies have demonstrated remarkable efficacy for patients with certain B cell driven hematological malignancies, further studies are required to broaden the use of CAR-T cell therapy against other hematological malignancies. Moreover, treatment failure still occurs for a significant proportion of patients. CAR antigen loss on cancer cells is one of the most common reasons for cancer relapse. Additionally, immune evasion can arise due to the hostile immunosuppressive tumor microenvironment and the impaired CAR-T cells in vivo persistence. Other than direct antitumor activity, the adverse effects associated with CAR-T cell therapy are another major concern during treatment. As a newly emerged treatment approach, numerous novel preclinical studies have proposed different strategies to enhance the efficacy and attenuate CAR-T cell associated toxicity in recent years. The major obstacles that impede promising outcomes for patients with hematological malignancies during CAR-T cell therapy have been reviewed herein, along with recent advancements being made to surmount them.
format Online
Article
Text
id pubmed-9557333
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95573332022-10-14 CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies Huang, Jiawen Huang, Xiaobing Huang, Juan Front Immunol Immunology In the past decade, the emergence of chimeric antigen receptor (CAR) T-cell therapy has led to a cellular immunotherapy revolution against various cancers. Although CAR-T cell therapies have demonstrated remarkable efficacy for patients with certain B cell driven hematological malignancies, further studies are required to broaden the use of CAR-T cell therapy against other hematological malignancies. Moreover, treatment failure still occurs for a significant proportion of patients. CAR antigen loss on cancer cells is one of the most common reasons for cancer relapse. Additionally, immune evasion can arise due to the hostile immunosuppressive tumor microenvironment and the impaired CAR-T cells in vivo persistence. Other than direct antitumor activity, the adverse effects associated with CAR-T cell therapy are another major concern during treatment. As a newly emerged treatment approach, numerous novel preclinical studies have proposed different strategies to enhance the efficacy and attenuate CAR-T cell associated toxicity in recent years. The major obstacles that impede promising outcomes for patients with hematological malignancies during CAR-T cell therapy have been reviewed herein, along with recent advancements being made to surmount them. Frontiers Media S.A. 2022-09-28 /pmc/articles/PMC9557333/ /pubmed/36248810 http://dx.doi.org/10.3389/fimmu.2022.1019115 Text en Copyright © 2022 Huang, Huang and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Huang, Jiawen
Huang, Xiaobing
Huang, Juan
CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
title CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
title_full CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
title_fullStr CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
title_full_unstemmed CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
title_short CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
title_sort car-t cell therapy for hematological malignancies: limitations and optimization strategies
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557333/
https://www.ncbi.nlm.nih.gov/pubmed/36248810
http://dx.doi.org/10.3389/fimmu.2022.1019115
work_keys_str_mv AT huangjiawen cartcelltherapyforhematologicalmalignancieslimitationsandoptimizationstrategies
AT huangxiaobing cartcelltherapyforhematologicalmalignancieslimitationsandoptimizationstrategies
AT huangjuan cartcelltherapyforhematologicalmalignancieslimitationsandoptimizationstrategies